03 September 2018
A new report by visiongain predicts that the Global Needle-Free Delivery Technology market will reach $2,093.9m in 2020. This forecast and others appear in Needle-Free Delivery Technology Market Forecast 2016-2026: Analysis and Forecasts for Jet Injector Technologies and Competing Technologies including Novel Needle Technology, Inhaler Technology and Microneedle Technology with an Assessment of Leading Companies including Antares, Zogenix and 3M—published in August 2016. Visiongain is a business information provider based in London, UK.
Needle-Free Delivery Technology Market Forecast 2016-2026: Analysis and Forecasts for Jet Injector Technologies and Competing Technologies including Novel Needle Technology, Inhaler Technology and Microneedle Technology with an Assessment of Leading Companies including Antares, Zogenix and 3M report examines the current and future trends in the growing needle-free delivery technology market. Needle-free delivery technologies will become more widely used in the next ten years. The need for improved needle-free delivery technologies and demand for less invasive drug administration procedures will be a major driver for the needle-free delivery technologies market. In addition, the growing diabetic patient population and need for improved patient compliance for children/elderly in most developed markets will help to drive the demand for needle-free delivery technologies.
In this report, we examine in detail the needle-free delivery technology market, and provide analyses and forecasts for regional and national markets. Historical revenues have also been added to strengthen our analysis to demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.
Visiongain’s report provides revenue forecasts to 2026 for the global medical laser systems market and the leading regional and national medical laser markets. The report discusses selected leading companies in the market. These companies include Antares Pharma, Beckton Dickinson and Company (BD), Bioject Medical Technologies, PharmaJet, Zogenix and 3M.
Needle-Free Delivery Technology Market Forecast 2016-2026: Analysis and Forecasts for Jet Injector Technologies and Competing Technologies including Novel Needle Technology, Inhaler Technology and Microneedle Technology with an Assessment of Leading Companies including Antares, Zogenix and 3M adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on firstname.lastname@example.org
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 61
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional that needs independent, high quality, original analyses to inform their strategic decisions.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.